Brokerages Set Aura Biosciences, Inc. (NASDAQ:AURA) Target Price at $23.00

Shares of Aura Biosciences, Inc. (NASDAQ:AURA) have been given an average recommendation of “Buy” by the seven analysts that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $23.00.

Several research analysts have recently weighed in on the stock. BTIG Research upped their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a report on Friday, October 18th. JMP Securities boosted their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Scotiabank boosted their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research report on Friday, October 18th. Finally, Cowen reissued a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th.

Insider Buying and Selling at Aura Biosciences

In related news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $9.85, for a total value of $72,722.55. Following the completion of the transaction, the chief technology officer now owns 121,132 shares in the company, valued at $1,193,150.20. This trade represents a 5.74 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Los Pinos Elisabet De sold 24,992 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the transaction, the insider now owns 329,847 shares of the company’s stock, valued at approximately $3,971,357.88. This trade represents a 7.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 67,259 shares of company stock worth $780,699 over the last ninety days. Insiders own 5.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in AURA. Long Focus Capital Management LLC raised its holdings in Aura Biosciences by 113.4% in the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after buying an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. raised its holdings in Aura Biosciences by 194.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after purchasing an additional 216,266 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after purchasing an additional 48,549 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Aura Biosciences by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares during the last quarter. Finally, SG Americas Securities LLC bought a new position in Aura Biosciences during the 3rd quarter worth approximately $169,000. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Stock Down 3.5 %

Aura Biosciences stock opened at $9.97 on Tuesday. The stock has a market capitalization of $494.61 million, a PE ratio of -5.81 and a beta of 0.33. Aura Biosciences has a twelve month low of $6.63 and a twelve month high of $12.38. The company has a 50 day moving average of $9.75 and a 200-day moving average of $8.50.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.02. Equities analysts anticipate that Aura Biosciences will post -1.7 EPS for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.